BRISTOL MYERS SQUIBB

Cambridge Cognition Holdings announced CANTAB assessments' role in Bristol Myers Squibb's Phase 3 trials for schizophrenia drug Cobenfy, targeting M1 and M4 receptors. CANTAB showed cognitive improvement in patients, highlighting its effectiveness in clinical trials and supporting digital assessment technologies for better trial accuracy and efficiency.

Cambridge Cognition's CANTAB tool supported FDA approval of Bristol Myers Squibb's schizophrenia drug, Cobenfy, marking a significant treatment advancement. CANTAB's role in clinical trials highlighted cognitive improvements, underscoring its importance in developing new schizophrenia treatments.

The FDA approved an injectable version of Bristol Myers Squibb's cancer drug Opdivo, branded as Opdivo Qvantig, for most previously approved adult solid tumor indications. This new form, co-formulated with Halozyme Therapeutics' technology, offers a more convenient treatment option, priced similarly to the IV version, aiming to sustain sales as older drug patents expire.

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize patient care. These include AWIQLI® for diabetes, CagriSema for obesity, and IMDELLTRA™ for lung cancer, showcasing advancements in AI, machine learning, and regulatory innovation to improve global health outcomes.

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize healthcare. These drugs, leveraging AI, machine learning, and novel mechanisms, aim to address unmet medical needs, improve patient outcomes, and achieve blockbuster status by 2030.

The 2025 Drugs to Watch™ report by Clarivate highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, expected to achieve blockbuster status or revolutionize treatment by 2030. It emphasizes advancements in AI, machine learning, and regulatory frameworks, showcasing the life sciences sector's resilience and innovation in improving global patient care.

Aer Therapeutics initiated a Phase 2a study, AER-01-002, testing fexlamose's safety and efficacy in 100 mucus plug-high COPD patients. Using CT scans for precise patient selection, the study aims to improve lung function and symptoms. Fexlamose, showing promise in Phase 1, targets mucus plugs, a significant unmet need in COPD treatment.

Galapagos focuses on cancer cell therapy, reducing workforce by 40%. Novo Nordisk expands AI drug research to obesity and diabetes. Orbis Medicines secures €90M for oral peptide drugs. FDA approves notable regenerative and rare disease treatments. Pfizer ends Sangamo alliance. Axsome aims for FDA filing in Alzheimer’s agitation. Bristol Myers Squibb gains FDA nod for injectable cancer drug. Corxel Pharmaceuticals enters obesity meds race. 3D medical animation revolutionizes healthcare education. Sotyktu shows promise in psoriatic arthritis. Eli Lilly’s Zepbound approved for sleep apnea. SandboxAQ raises $300M for drug discovery. SiteOne secures $100M for non-opioid pain meds.

Cambridge Cognition's CANTAB digital assessments played a key role in Bristol Myers Squibb's trials for Cobenfy, a novel schizophrenia treatment targeting M1 and M4 muscarinic receptors. Cobenfy showed improved efficacy in reducing schizophrenia symptoms and enhancing cognitive performance, validating CANTAB's capabilities in clinical trials.

Sensyne Health signed a 5-year SRA with MKUH to apply AI on anonymised patient data for new medicine research. MKUH gets equity, shares, and IT investment, increasing NHS Trusts' total Sensyne ownership to 10.86%. MKUH also receives royalties for NHS reinvestment. Sensyne also partnered with BMS for MPN research, marking its fourth major pharma collaboration.